FAQs

LEO Pharma Open Innovation openly discloses the science we offer and some of our corporate interests. We provide open and free access to some of our specialised research capabilities, without asking for any commitments from the partner. The structure of your molecule remains confidential as we don't ask for the partner to disclose it. There are no further business obligations and the data we generate is owned by the partner, whom is free to use it in any way, including in publications.

LEO Pharma Open Innovation is a collaborative space created to explore partnerships and the latest research using disease-relevant in vitro assays as an initial stepping stone towards finding the next generation of treatments for skin disease together. The open innovation platform allows insight and access to some of LEO Pharma's unique research tools in order to test external molecules for disease-relevant effects, but without the obligation to disclose confidential information (such as the structure of your molecule) or to relinquish intellectual property. By openly disclosing the assays we offer and some of our corporate interests, we hope that someone out there will have a resource, piece of information or an idea that we didn’t know about before, to provide a solution for people with skin diseases.

No, it does not. 'Open' in this context refers to the open disclosure and availability of our disease-relevant assays. Participation in LEO Pharma Open Innovation is an agreement between LEO Pharma and you, the partner. Your decision, compounds, results and conclusion will not be kept confidential by us, and not communicated to anyone outside of LEO Pharma, unless specifically agreed.

The document which you can download here is an agreement between LEO Pharma and you (the partner) which specifies the details, including securing confidentiality and what we do in the collaboration. It covers what sometimes is referred to as a Material Transfer Agreement (MTA). It also states that LEO Pharma will not use the compounds in any other way than agreed upon and that you consider some points when agreeing to nominate compounds for testing in the LEO Pharma Open Innovation platform. One of the main points of the contract is to ensure that your assets (molecules) are safe, protected and that the partner is in control of the process.

As long as you are a recognised company or institution and provide the necessary registration information– yes! However, LEO Pharma can choose not to allow access if the registration criteria are not met, or if there is a potential issues with LEO Pharma code of conduct or business otherwise.

In short, no - we can't test anything. The process is designed for testing small molecules dissolved in DMSO that allows for testing of any such molecule of your choosing. LEO Pharma Open Innovation invites you to test compounds you believe will have an effect in the disclosed in vitro assays, and to explore science with the intention of further collaboration. We will not filter or select what we test, but by giving you the details of the assays we hope that you can make a sensible judgement on whether your molecule has the potential to produce an interesting result. However, if we for any reason suspect a hazard issue we will of course not test or handle such a molecule.

Currently our assays are designed to test compounds dissolved in DMSO which is usually not a good vehicle for larger proteins such as antibodies. However, we are able to run some tests using a non-standard process allowing for water, or PBS-soluble molecules in some of the open innovation assays, one example being the keratinocyte CCL2-release assays. We will discuss on an case-by-case level when non-DMSO is required (*DMSO is a solvent that is very common when working with small molecules), so please reach out to see if there is an option.